A research study for an investigational respiratory syncytial virus (RSV) vaccine in older adults

Overview

Are you ready to help in the fight against RSV?
We’re preparing for respiratory syncytial virus (RSV) season, and we’re looking for people who can help us advance an investigational vaccine for RSV.

RSV is a leading cause of respiratory illness in older adults that can lead to hospitalization. No specific prevention or treatment options currently exist. You may be eligible for the Renoir study if you are 60 years of age or older and generally healthy or have stable chronic conditions.

If you qualify and choose to take part, you will be in the study for three RSV seasons (about three years). By participating in the Renoir study, you could be a part of vaccine progress for older adults.

Ages

60 and over

Study Topics

Vaccine

Application for Current Clinical Research Study

* indicates required
() - (###) ###-####
Best Time to Reach You
Optin

Are you ready to help in the fight

against RSV?

By participating in the Renoir study, you can help us learn if an investigational vaccine can help fight off RSV infection and disease in older adults. RSV can cause pneumonia, worsening of congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or other problems that may lead to hospitalization. When you participate in a study, you’re helping to represent both your community and all people who are affected by RSV. Your participation could make a difference.

This research study is enrolling people who:

Are 60 years of age and older

Are generally healthy or have stable chronic conditions

Do not have a history of severe side effects from or allergic reactions to vaccines

Participation lasts for three RSV seasons (about three years)